medigraphic.com
ISSN 1870-199X (Print)
Órgano oficial de la Facultad de Odontología, UNAM

2020, Number 1

<< Back Next >>

Rev Odont Mex 2020; 24 (1)

Aspirin exacerbated respiratory disease (AERD), a disease little known to the dentist. Study guide and management

Prado BNY, Pérez SH, Badillo BM

Language: Spanish
References: 23
Page: 20-29
PDF size: 177.13 Kb.


ABSTRACT

Aspirin-exacerbated respiratory disease (AERD) is chiefly characterized by the following symptoms: nasal polyps, chronic sinusitis, asthma, and sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit the enzyme cyclooxygenase-1 (COX-1). Ingestion of aspirin and most NSAIDs may result in a spectrum of allergic reactions manifested mainly in the upper and/or lower airways. The allergic reaction can become severely complicated and produce laryngospasm and/or bronchospasm. Objective: To create a simple study guide to alert the general dentist in the analgesic management of patients with AERD. Conclusion: AERD is a chronic, underdiagnosed disease that requires performing a patient’s careful medical history and interrogation of prior history of both pharmacological and food allergies, with special attention in asthmatic patients, as asthma may trigger allergic reactions to our conventional analgesic management secondary to dental treatment.


REFERENCES

  1. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Inmmunol Res. 2011; 3 (1): 3-10.

  2. Buchheit MK, Laidlaw MT. Update on the management of aspirin-exacerbated respiratory disease. Allergy Asthma Inmmunol Res. 2016; 8 (4): 298-304.

  3. Hernández MKE, Cardona R. Enfermedad respiratoria exacerbada por aspirina. Revisión a partir de casos clínicos. Rev Alerg Mex. 2017; 65 (1): 78-91.

  4. Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract. 2017; 5 (3): 537-545.

  5. Gajardo OP, Fonseca AX. Intolerancia a la aspirina en pacientes con piloposis nasal y asma bronquial. Rev Otorrinolaringol Cir Cabeza Cuello. 2009; 69: 157-168.

  6. Castilla RJL, Vargas CME, Rodríguez BRA, Galicia TJ, Castrejón VMI. Prevalencia de intolerancia a salicilatos en pacientes con poliposis nasosinusal. Revista Alergia México. 2015; 62 (3): 202-210.

  7. Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ et al. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016; 6 (4): 385-391.

  8. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015; 135 (3): 676-681.

  9. Karakaya G, Celebioglu E, Kalyoncu AF. Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma. Respiratory Medicine. 2013; 107 (7): 967-974.

  10. Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2017; 139 (3): 764-766.

  11. Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease. New prime suspects. N Engl J Med. 2016; 374: 484-488.

  12. Cowburn AS, Sladek K, Soja J, Adamek L, Lam K, Austen ST et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998; 101 (4): 834-846.

  13. Sakalar EG, Muluk NB, Kar M, Cingi C. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol. 2017; 274 (3): 1292-1300.

  14. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012; 119 (16): 3790-3798.

  15. Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013; 33 (2): 163-176.

  16. Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. 2016; 30 (6): 407-413.

  17. Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol. 2003; 24 (2): 113-124.

  18. Jares EJ, Sánchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez M et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol. 2014; 113 (3): 282-289. doi: 10.1016/j.anai.2014.06.019.

  19. Klak A, Raciborski F, Krzych-Falta E, Opoczynska-Swiezewska D, Szymanski J, Lipiec A et al. Persons with allergy symptoms use alternative medicine more often. Pneumonol Alergol Pol. 2016; 84 (5): 251-257.

  20. Hanns WB. Salicylate intolerance. Dtsch Arzteb Int. 2008; 105 (8): 137-142.

  21. Wood A, Baxter G, Thies F, Kyle J, Duthie G. A systematic review of salicylates in foods: estimated daily intake of Scottish population. Mol Nutr Food Res. 2011; 55: S7-14.

  22. Calderón JC, Dávila F, Mantilla R, Chérrez A, Calero E, Cabrera D et al. Knowledge and attitudes about aspirin exacerbated respiratory disease among Ecuadorian physicians. Rev Alerg Mex. 2017; 64 (1): 13-23.

  23. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007; 98 (2): 172-174.




2020     |     www.medigraphic.com